ClinicalTrials.gg
RecruitingNCT07688577Updated Nov 4, 2026

XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors

A Phase 1/2 interventional study of XTX501 in Metastatic NSCLC - Non-Small Cell Lung Cancer and Advanced Solid Tumor, sponsored by Xilio Development, Inc.. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Xilio Development, Inc. · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 2, 2026Now RecruitingFirst site in United States+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
180
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 523 open to participants now, 896 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Planned enrollment
678th of 3,001
180 · median 56
Started
2026
with 133 others
Phase 1/2
487 of 3,374
120 open now
Primary completion
2029-11
later than 762 of 894 live
Registered
3,327th of 3,374
by date

Among the 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 678th largest by planned enrollment of the 3,001 interventional ones that give a count, is one of 134 that started in 2026, is one of 487 in phase 1/2, reaches primary completion later than 762 of the 894 other live ones, and was the 3,327th registered.

Carcinoma, Non-Small-Cell Lung

7,638 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

523 of the 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

517 more — sign in →

All 523 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 226 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX501 as monotherapy in participants with metastatic non-small cell lung cancer (NSCLC) and select advanced solid tumors.

Read the detailed description

This is a first-in-human, Phase 1/2, multicenter, open-label study designed to evaluate the safety, tolerability, PK, pharmacodynamics, immunogenicity, and antitumor activity of XTX501, an investigational bispecific PD-1/masked IL-2 in participants with metastatic NSCLC and select advanced solid tumors.

Phase 1, Part 1A will examine XTX501 monotherapy in a Bayesian Optimal Interval design to determine the maximum tolerated dose up to 10 dose regimens.

Phase 1, Part 1B will further evaluate the safety and antitumor activity of XTX501 at dose regimens under consideration for the recommended Phase 2 dose(s).

Phase 2 will further evaluate the efficacy of the selected recommended Phase 2 dose(s).

03

Conditions studied

  • Metastatic NSCLC - Non-Small Cell Lung Cancer
  • Advanced Solid Tumor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • at baseline per v1.1
  • performance status of 0 or 1
  • Adequate organ function
  • NSCLC:

    • Must have confirmed metastatic NSCLC.
    • Tumor must have been assessed for EGFR and ALK per local standard of practice; patients with these driver mutations are excluded.
    • Patients with tumors known to have the following alterations are excluded: ROS1, RET, MET, , NTRK 1/2/3.
    • Patients must have previously derived clinical benefit from a /PD-L1 inhibitor or PD-1/PDL-1 bispecific without progression for at least 6 months.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with IL-2
  • History of significant pulmonary disease
  • History of cardiovascular disease
  • Active
  • Pregnant or breastfeeding

In Phase 1, participants with select additional solid tumor types may be enrolled.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Phase 1 - XTX501 Monotherapy Dose Escalation and Backfill

    Part 1A will examine XTX501 monotherapy in a Bayesian Optimal Interval design to determine the maximum tolerated dose up to 10 dose regimens. Up to 60 participants may be enrolled. Part 1B will further evaluate the safety and antitumor activity of XTX501 at dose regimens under consideration for the recommended Phase 2 dose(s). Up to 40 participants may be enrolled

    Drug: XTX501

  • Experimental
    Phase 2- XTX501 Monotherapy Dose Expansion in metastatic NSCLC

    Phase 2 will further evaluate the efficacy of the selected recommended Phase 2 dose(s) in participants with metastatic NSCLC. Up to 80 participants may be enrolled

    Drug: XTX501

Interventions

  • DrugXTX501

    XTX501 monotherapy

06

What researchers measure

Primary outcomes

  1. Incidence of Dose Limiting Toxicities (DLTs) in Part 1A

    Time frame: Cycle 1 Day 1 up to just prior to the second dose of study drug (approximately 21 days)

  2. Incidence of treatment-emergent adverse events (Phase 1 and Phase 2)

    Time frame: Up to Safety Follow Up Period (90 [+7] days after the last dose)

  3. Incidence of serious adverse events (Phase 1 and Phase 2)

    Time frame: Up to Safety Follow Up Period (90 [+7] days after the last dose)

  4. Incidence of significant change from baseline in clinical laboratory values (Phase 1 and Phase 2)

    Time frame: Up to Safety Follow Up Period (90 [+7] days after the last dose)

  5. Investigator-assessed objective response rate (ORR) per RECIST v1.1 (Phase 2)

    Time frame: Up to Safety Follow Up Period (90 [+7] days after the last dose)

Secondary outcomes

  1. Investigator-assessed objective response rate (ORR) per RECIST v1.1 (Phase 1)

    Time frame: Up to Safety Follow Up Period (90 [+7] days after the last dose)

  2. Investigator-assessed duration of response (DOR) per RECIST v1.1 (Phase 1 and Phase 2)

    Time frame: Up to Safety Follow Up Period (90 [+7] days after the last dose)

  3. Investigator-assessed disease control rate (DCR) per RECIST v1.1 (Phase 2)

    Time frame: Up to Safety Follow Up Period (90 [+7] days after the last dose)

  4. Investigator-assessed progression free survival (PFS) per RECIST v1.1 (Phase 2)

    Time frame: Up to Safety Follow Up Period (90 [+7] days after the last dose)

  5. Incidence and persistence of antidrug antibodies (ADAs) (Phase 1 and Phase 2)

    Time frame: Up to End of Treatment (within 10 days of the decision to discontinue XTX501)

  6. Maximum observed plasma concentration (Cmax) (Phase 1 and Phase 2)

    Time frame: Up to End of Treatment (within 10 days of the decision to discontinue XTX501)

  7. Time of maximum observed concentration (Tmax) (Phase 1 and Phase 2)

    Time frame: Up to End of Treatment (within 10 days of the decision to discontinue XTX501)

  8. Trough concentrations (Ctrough) (Phase 1 and Phase 2)

    Time frame: Up to End of Treatment (within 10 days of the decision to discontinue XTX501)

  9. Area under the curve (AUC) (Phase 1 and Phase 2)

    Time frame: Up to End of Treatment (within 10 days of the decision to discontinue XTX501)

  10. Half-life (t1/2) (Phase 1 and Phase 2)

    Time frame: Up to End of Treatment (within 10 days of the decision to discontinue XTX501)

  11. Systemic clearance (CL) (Phase 1 and Phase 2)

    Time frame: Up to End of Treatment (within 10 days of the decision to discontinue XTX501)

  12. Volume of distribution (Vd) (Phase 1 and Phase 2)

    Time frame: Up to End of Treatment (within 10 days of the decision to discontinue XTX501)

07

Study locations

3 of 3 sites recruiting
  • Investigator Site
    Canton, Ohio 44718, United States
    Recruiting
  • Investigator Site
    Fort Worth, Texas 76104, United States
    Recruiting
  • Investigator Site
    Fairfax, Virginia 22031, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Nov 2029, 37 months after the start.

Of 312 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 37 months is below that.

Counting every sponsor, half of 436 studies reached it within 63 months; a quarter within 41 and three quarters within 80.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Nov 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2026
First posted
Jul 7, 2026
StartActual
Oct 21, 2026was Aug 2026
Primary completionEst.
Nov 2029
CompletionEst.
Nov 2029
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 2, 2026
Sites
3 sites added — first site in United States
Show 3 added (3 United States)
  • Investigator Site · Canton, United States
  • Investigator Site · Fort Worth, United States
  • Investigator Site · Fairfax, United States
Nov 2, 2026
Start date
Aug 2026→Oct 21, 2026 (actual)
Nov 2, 2026
Enrollment
140→180
Nov 2, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Investigator Site · Canton, United StatesContact removed (no phone or email listed)
  • Investigator Site · Fort Worth, United StatesContact removed (no phone or email listed)
  • Investigator Site · Fairfax, United StatesContact removed (no phone or email listed)
Nov 4, 2026
Show all 2 updates
  1. Nov 4, 2026
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Investigator Site · Canton, United StatesContact removed (no phone or email listed)
    • Investigator Site · Fort Worth, United StatesContact removed (no phone or email listed)
    • Investigator Site · Fairfax, United StatesContact removed (no phone or email listed)
  2. Nov 2, 2026
    Not yet recruiting→Recruiting
    3 sites added — first site in United States
    Show 3 added (3 United States)
    • Investigator Site · Canton, United States
    • Investigator Site · Fort Worth, United States
    • Investigator Site · Fairfax, United States
    Start date Aug 2026→Oct 21, 2026 (now actual)
    Enrollment 140→180
    + 2 other changes: verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07688577
Lead sponsor
Xilio Development, Inc.
Responsible party
Sponsor
First posted
Jul 7, 2026
Start date
Oct 21, 2026
Primary completion
Nov 2029 (estimated)
Completion
Nov 2029 (estimated)
Last update
Nov 4, 2026

Study contacts

Xilio Medical Affairs
Contact
medicalaffairs@xiliotx.com
(857) 524-2466

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion